Skip to main content
. Author manuscript; available in PMC: 2012 Jul 14.
Published in final edited form as: J Pharmacol Sci. 2012 May 22;119(2):131–138. doi: 10.1254/jphs.12031fp

Fig. 1.

Fig. 1

Renal angiotensin II (AngII) contents. The vehicle-treated mice show a greater AngII content in the kidney than C57BL mice. Val-Val15 tends to suppress the renal AngII level in type 2 diabetic KKAy mice, but the effect is not significant. Both Val-Val50 and Val-Val+Ali normalize the accumulation of AngII in the kidney. *P < 0.05 vs. C57BL mice, #P < 0.05 vs. vehicle group. Val-Val15: 15 mg/kg per day of valsartan for 10 weeks, Val-Val50: treatment with 15 mg/kg per day of valsartan for the first 4 weeks and treatment with 50 mg/kg per day of valsartan from weeks 4 to 10, Val-Val+Ali: treatment with 15 mg/kg per day of valsartan for 10 weeks and additional treatment with 25 mg/kg per day of aliskiren from weeks 4 to 10.